BLA 021081 · Sanofi Aventis US
Lantus Solostar
Insulin Glargine Recombinant · Injection · Insulin Analog
NovelLast checked: Nov 20, 2026Latest source record: Jun 29, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Apr 20, 2000
Approved uses
5
Original approval plus efficacy supplements
Registered trials
9
3 Phase 3, 0 recruiting
FAERS reports
202,872
112,860 serious, 12,531 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 2, 2025.
LANTUS is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. LANTUS is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 ) Limitations of Use Not recommended for the treatment of diabetic ketoacidosis. ( 1 ) Limitations of Use LANTUS is not recommended for the treatment of diabetic ketoacidosis.
Mechanism: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 17, 2015 Supplement 63 · Efficacy LetterLabel
- Oct 18, 2013 Supplement 57 · Efficacy LabelLetter
- Sep 9, 2009 Supplement 34 · Efficacy LabelReviewLetter
- May 1, 2003 Supplement 5 · Efficacy LabelLetter
- Apr 20, 2000 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
2 products under this application
- LANTUS SOLOSTAR · INSULIN GLARGINE RECOMBINANT 300 UNITS/3ML (100 UNITS/ML) · INJECTABLE, INJECTION · Prescription
- LANTUS · INSULIN GLARGINE RECOMBINANT 100 UNITS/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Glargine Recombinant" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) PatientsPivotal-lookingCompleted
Emory UniversityAcademic, hospital or other
NCT01792830 · 175 participants · Start Oct 2012 · Primary completion Feb 2014
Drug: Metformin; Glargine insulin and 1 more · For: Poor Glycemic Control
Sites: Atlanta, Georgia · 3 sites in all
- Insulin in Total Parenteral NutritionPivotal-lookingCompleted
Fundación Pública Andaluza Progreso y SaludAcademic, hospital or other
NCT02706119 · 163 participants · Start Jul 1, 2016 · Primary completion Mar 31, 2018
Drug: Subcutaneous glargine insulin; Regular insulin added to TPN bag · For: Diabetes Mellitus
Sites: Ferrol, Spain; Mérida, Spain; Palma de Mallorca, Spain · 32 sites in all
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes MellitusPivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01194245 · 135 participants · Start Aug 2010 · Primary completion Aug 2011
Drug: Insulin lispro; recombinant human hyaluronidase PH20 and 3 more · For: Diabetes Mellitus, Type 1
Sites: Escondido, California; La Jolla, California; San Mateo, California · 19 sites in all
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes MellitusPivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01194258 · 132 participants · Start Aug 2010 · Primary completion Aug 2011
Drug: Insulin lispro; Insulin aspart and 3 more · For: Diabetes Mellitus, Type II
Sites: Concord, California; Encino, California; Escondido, California · 22 sites in all
- Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DMPivotal-lookingCompleted
WockhardtIndustry
NCT01357603 · 111 participants · Start Jun 2011 · Primary completion May 2012
Drug: Glargine · For: Type1 Diabetes
Sites: Chula Vista, California
Cook County HealthGovernment (non-federal)
NCT00732524 · 80 participants · Start Sep 2004 · Primary completion Apr 2006
Drug: Glipizide; Glipizide and Glargine · For: Type 2 Diabetes
Sites: Chicago, Illinois
Halozyme TherapeuticsIndustry
NCT00883558 · 48 participants · Start May 2009 · Primary completion Feb 2010
Drug: Insulin Lispro; regular human insulin and 2 more · For: Diabetes Mellitus, Type 1
Sites: Aurora, Colorado; Miami, Florida; Detroit, Michigan · 8 sites in all
- Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic PatientsPivotal-lookingWithdrawn
WockhardtIndustry
NCT01352663 · 0 participants
Drug: Wockhardt's Insulin Analogue (Recomb); Lantus® · For: Type I Diabetes
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased29,554
- off label use13,004
- nausea8,711
- drug ineffective8,451
- inappropriate schedule of product administration8,366
- blood glucose decreased8,334
- hypoglycaemia7,179
- product storage error6,908
- visual impairment6,568
- diarrhoea6,177
- fatigue6,032
- dyspnoea5,652
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,035 |
| 2005 | 1,804 |
| 2006 | 3,270 |
| 2007 | 3,327 |
| 2008 | 2,949 |
| 2009 | 3,916 |
| 2010 | 5,398 |
| 2011 | 6,269 |
| 2012 | 5,590 |
| 2013 | 8,148 |
| 2014 | 12,103 |
| 2015 | 18,871 |
| 2016 | 12,475 |
| 2017 | 11,285 |
| 2018 | 16,789 |
| 2019 | 13,842 |
| 2020 | 11,767 |
| 2021 | 10,694 |
| 2022 | 9,994 |
| 2023 | 8,875 |
| 2024 | 10,646 |
| 2025 | 13,310 |
| 2026 | 10,512 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lantus (Insulin Glargine,Hum.Rec.Anlog)
2024 spending
$140M
Beneficiaries
271,761
1,116,800 claims
Per beneficiary
$515
$6.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,055,722,607 |
| 2021 | $958,653,939 |
| 2022 | $833,484,770 |
| 2023 | $735,735,411 |
| 2024 | $139,894,057 |
Part D: Lantus Solostar (Insulin Glargine,Hum.Rec.Anlog)
2024 spending
$699M
Beneficiaries
1,415,422
5,570,732 claims
Per beneficiary
$494
$6.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,663,360,232 |
| 2021 | $2,831,447,261 |
| 2022 | $2,873,658,630 |
| 2023 | $3,157,233,282 |
| 2024 | $699,132,486 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study.
Blevins TC, Raiter Y, Sun B, et al. · BioDrugs 2022 · Randomized Controlled Trial
Sponsor: Sanofi · Also marketed as Lantus
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.